

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILIN	IG DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642,531	08/	15/2003	Elizabeth-France Marillia	3015-6072US	3187
24247	7590	12/30/2004		EXAM	INER
TRASK BI	TTIS		KOROMA, BARBA M		
P.O. BOX 2	550				
SALT LAK	SALT LAKE CITY, UT 84110			ART UNIT	
	•			1638	

DATE MAILED: 12/30/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Applicati n N .	Applicant(s)
	10/642,531	MARILLIA ET AL.
Office Action Summary	Examiner	Art Unit
	Barba M. Koroma	1638
The MAILING DATE of this communication app Period for Reply	pears n the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tir y within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	mely filed /s will be considered timely. In the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 15 A	<u>ugust 2003</u> .	
2a) This action is FINAL . 2b) This	action is non-final.	
3) Since this application is in condition for alloward closed in accordance with the practice under E		
Disposition of Claims		
 4) Claim(s) 1-20 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-20 are subject to restriction and/or example. 	wn from consideration.	·
Application Papers		
9) The specification is objected to by the Examine		•
10) The drawing(s) filed on is/are: a) acc		
Applicant may not request that any objection to the		
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex		
Pri rity under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicat rity documents have been receiv u (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s)	_	
1) Notice of References Cited (PTO-892)	4) Interview Summary Paper No(s)/Mail D	
 Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 		Patent Application (PTO-152)

Art Unit: 1638

DETAILED ACTION

Election/Restrictions

Claims 1-20 are drawn to a genetically transformed plant, comprising a means for modulating mitochondrially generated acetyl-CoA and/or respiration rate as compared to a genomically-unmodified plant of the same genotype, using anti-sense nucleotides targeting the Brassica pyruvate dehydrogenase kinase protein, and a ubiquitin or phaseolin gene promoter operatively linked to the means for reducing respiration.

Applicants are reminded that different nucleotide sequences are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute **independent and distinct** inventions within the meaning of 35 U.S.C. 121.

Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq.

This requirement is not to be construed as a requirement for an election of species, since each nucleotide sequence is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.

Application/Control Number: 10/642,531

Art Unit: 1638

Claims 2, 11, and 16 specifically utilize sequences selected from among SEQ ID Nos. 1, 2, 3, and 4. Each sequence has a unique nucleotide drawn from a different species. As such, each nucleotide is considered to be patentably distinct. Furthermore, a search of more than one (1) of the sequences presents an undue burden on the Patent and Trademark Office due to the complex nature of the search and corresponding examination of more than one (1) of the claimed sequences, and the use of its antisense sequence in the claimed method. In view of the foregoing, one (1) sequence is considered to be a reasonable number of sequences for examination. Accordingly, Applicants are required to elect one (1) sequence from SEQ ID Nos. Note that this is not a species election.

Page 3

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Contact Information

Any inquiry concerning this or earlier communications from the Examiner should be directed to Barba Koroma, whose telephone number is 571-272-0899. The Examiner can normally be reached from 8:00 A.M to 5:30 P.M. If attempts to reach the Examiner by telephone

Art Unit: 1638

are unsuccessful, the Examiner's supervisor, Amy Nelson, can be reached at 571-272-0804. The fax phone numbers for the organization where this application or proceeding is assigned is 571 273 8300. Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

BMK

ASHRVA D. MEHTA, PH.D. PRIMARY EXAMINER